Healthscope exits GP market, boosts tech investment in pathology

Private hospital and pathology laboratory operator Healthscope has reported a decline in net profit of almost 40 per cent for the 2017 financial year, mainly due to a write-down from the sale of its 43-strong medical centre portfolio, but the company says it will continue to invest in infrastructure and technology.

The ASX-listed multinational's new CEO, former Telstra executive Gordon Ballantyne, highlighted the New Zealand pathology division as a bright spot with increased investment in technology leading to efficiency gains, but said the hospital division was suffering from soft market conditions.

Posted in Australian eHealth

Tags: HealthLink, Sysmex, Healthscope

You need to log in to post comments. If you don't have a Pulse+IT website account, click here to subscribe.

Sign up for Pulse+IT eNewsletters

Sign up for Pulse+IT website access

For more information, click here.

Copyright © 2020 Pulse+IT Magazine
No content published on this website can be reproduced by any person for any reason without the prior written permission of the publisher.